Keystone Symposia on Antimicrobial Resistance and Microbiome

Keystone Symposia Presentation Details

Poster: Phase 2 Clinical Trial Design for CRS3123, a Novel Narrow-Spectrum Agent in Development to Treat C. difficile Infections